Overview

The Office of the Gene Technology Regulator (OGTR) is currently assessing an application from AstraZeneca Pty Ltd for its COVID-19 vaccine candidate, as detailed in the Gazette dated 18 December 2020. This Act was introduced to ensure that the importation, transport, storage, and disposal of the vaccine do not pose any risks to human health and the environment. The assessment is mandated under the Gene Technology Act 2000 (Cth), with the aim of regulating genetically modified and related organisms in Australia. The OGTR, in conjunction with the Therapeutic Goods Administration (TGA), is responsible for evaluating the application. The Regulator seeks public comment on the assessment by close of business on 18 January 2021, to facilitate a thorough evaluation process. Further information and contact details are available on the OGTR website and via their provided telephone number and email address.

Scope and Application

The scope and application of this legislative announcement pertain to the assessment of AstraZeneca’s COVID-19 vaccine candidate by the Office of the Gene Technology Regulator (OGTR). This process applies to AstraZeneca Pty Ltd as the entity seeking review for its modified virus vaccine, which necessitates scrutiny under both the OGTR and the Therapeutic Goods Administration (TGA) frameworks prior to any approval for use in Australia. The geographic reach of this assessment is national, focusing on the potential risks to human health and the environment associated with the import, transport, storage, and disposal of the vaccine. Public submissions are invited to provide insights on the assessment, which must be submitted by 18 January 2021. The announcement does not specify exclusions, exemptions, or thresholds for this particular application but indicates that the OGTR is open to public input as part of its regulatory process. The application of this assessment is further extended through the provided contact details and reference number for those wishing to engage with the review process.

Key Provisions

The primary operative sections of the Gazette C2020G01029 invite stakeholders to provide comments on the assessment of the AstraZeneca COVID-19 vaccine (section 1). This section outlines the need for review by both the Office of the Gene Technology Regulator (OGTR) and the Therapeutic Goods Administration (TGA) before the vaccine can be approved for use in Australia (section 1). The OGTR is tasked with investigating any potential risks to human health and the environment posed by the vaccine's import, transport, storage, and disposal (section 1). The Act imposes specific obligations and requirements on AstraZeneca Pty Ltd, the pharmaceutical company, as well as on the OGTR and TGA. AstraZeneca must submit an application for review by the OGTR and the TGA (section 1). The OGTR must assess the potential risks and seek public submissions by a specified deadline (section 1). The TGA is also required to review the vaccine for therapeutic efficacy and safety (section 1). Both regulators must ensure that any identified risks are adequately managed to protect public health and the environment. Breaches of the provisions outlined in the Act can result in various civil, criminal, or administrative consequences. While the Gazette does not specify the exact penalties, non-compliance with regulatory requirements can typically lead to enforcement actions by the relevant authorities. For instance, failure to submit a complete and accurate application by AstraZeneca could result in delays or refusal of approval. If risks are not properly managed, the regulators may take further action to protect public health, potentially including fines or other sanctions against the company. The precise penalties would depend on the nature and severity of the breach, in accordance with the relevant legislation governing the activities of the OGTR and TGA.